IFP Advisors, Inc - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 201 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2017. The put-call ratio across all filers is 0.47 and the average weighting 0.3%.

Quarter-by-quarter ownership
IFP Advisors, Inc ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$1,258
-87.1%
46
-91.2%
0.00%
Q1 2023$9,760
+74976.9%
525
+4.2%
0.00%
Q4 2022$13
-100.0%
504
-70.6%
0.00%
-100.0%
Q3 2022$38,000
+111.1%
1,717
+87.9%
0.00%0.0%
Q2 2022$18,000
-5.3%
914
-3.0%
0.00%
Q1 2022$19,000
+1800.0%
942
+3264.3%
0.00%
Q4 2021$1,000
-98.7%
28
-98.5%
0.00%
-100.0%
Q3 2021$78,000
-11.4%
1,865
-3.0%
0.00%0.0%
Q2 2021$88,000
-28.5%
1,922
-34.7%
0.00%0.0%
Q1 2021$123,000
+23.0%
2,942
+26.6%
0.00%
-50.0%
Q4 2020$100,0002,3240.00%
Q3 2020$000.00%
Q2 2020$000.00%
Q1 2020$000.00%
Q4 2019$000.00%
Q3 2019$0
-100.0%
0
-100.0%
0.00%
-100.0%
Q4 2018$132,000
-35.6%
9,225
-18.4%
0.01%0.0%
Q3 2018$205,000
+9.6%
11,300
+2.0%
0.01%0.0%
Q2 2018$187,000
-31.0%
11,075
-17.2%
0.01%
-33.3%
Q1 2018$271,0000.0%13,3750.0%0.01%0.0%
Q4 2017$271,000
+34.2%
13,375
+14.9%
0.01%
+50.0%
Q3 2017$202,000
+7.4%
11,636
-20.8%
0.01%0.0%
Q2 2017$188,000
+0.5%
14,686
+1.6%
0.01%
-11.1%
Q1 2017$187,000
+78.1%
14,460
+36.3%
0.01%
+80.0%
Q4 2016$105,000
-4.5%
10,610
+16.5%
0.01%
-16.7%
Q3 2016$110,000
+14.6%
9,111
-17.7%
0.01%
+20.0%
Q2 2016$96,000
+95.9%
11,077
+290.6%
0.01%
+66.7%
Q4 2015$49,0002,8360.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2017
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders